Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments...
September 04, 2018 12:15 ET | Source: BioCryst Pharmaceuticals, Inc.

CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks

—Safety and efficacy data support advancement of 750 mg dose as first oral therapy for acute HAE attacks— In a release issued under the same headline earlier today by BioCryst Pharmaceuticals, Inc....
September 04, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks

—Safety and efficacy data support advancement of 750 mg dose as first oral therapy for acute HAE attacks— RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,...
August 29, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 29, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Baird Global Healthcare Conference...
August 07, 2018 06:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Second Quarter 2018 Financial Results

RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2018. “Building...
August 06, 2018 16:01 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares...
August 06, 2018 06:00 ET | Source: BioCryst Pharmaceuticals, Inc.

U.S. FDA Grants Fast Track Designation for BioCryst’s BCX7353

RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments...
August 01, 2018 21:59 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals Prices Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of...
August 01, 2018 16:01 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals Commences Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) a biotechnology company focused on the development and commercialization of treatments...
July 27, 2018 09:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Announce Second Quarter 2018 Financial Results on August 7

RESEARCH TRIANGLE PARK, N.C., July 27, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2018 financial results will be reported on...